NCT05488626View on ClinicalTrials.gov

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Stage III Non-small Cell Lung Cancer
Interventions
DEVICE

Adaptive Radiotherapy

Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily online adaptation.

DEVICE

Non-Adaptive Radiotherapy

Standard fractionation external beam radiotherapy (60-66 Gy in 2 Gy/fraction) with daily image guidance.

DRUG

Chemotherapy

Concomitant chemotherapy per NCCN or other national guidelines.

DRUG

Immunotherapy

Adjuvant immunotherapy per national or institutional guidelines.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

Varian, a Siemens Healthineers Company

INDUSTRY

NCT05488626 - Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer | Biotech Hunter | Biotech Hunter